Skip to main content

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases


Start Date
End Date
Total Funding
€ 11 363 398
Funding Programme
European Countries Involved

Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented research effort that can only be achieved through collaboration between leading European laboratories and the pharmaceutical industry.

To meet this ambition the IMPRiND consortium will synergistically accelerate progress to map and target critical steps in the propagation, proteostatic response and protection against misfolded α-synuclein and tau.

Specifically we aim to

  • (1) identify disease-relevant assemblies, imprint their biological properties in vitro and generate homogeneous populations to assay and interfere with their pathogenic effects;
  • (2) develop and miniaturise assays to monitor secretion, uptake, clearance and oligomerisation using bimolecular fluorescence complementation of oligomeric species or transfer of untagged assemblies to fluorescently labelled fibril-naïve cells and measure markers of early proteotoxicity that are suitable for live imaging high content screens;
  • (3) deliver robust validation assays for these molecular events in complex cellular systems with greater functional resemblance to the native milieu of the brain such as iPSC-based and organotypic cultures
  • (4) standardise pathological readouts in animal models for in vivo validation of modifiers, correlate them with novel peripheral or in situ markers using microdialysis to accelerate the assessment of therapeutic interventions and relevance to humans, e.g. by transplantation of human iPSC neurons in animals;
  • (5) assess toxicity and druggability of potential targets. IMPRiND will construct this entire pipeline to examine the prion-like properties of α-synuclein and tau and test their tractability against disease progression.
Project partners

Aarhus Universitet

Abbvie Deutschland Gmbh & Co Kg

Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev

The Chancellor Masters And Scholarsof The University Of Cambridge

Sciprom Sarl

Novartis Pharma Ag

University Of Dundee

Idryma Iatroviologikon Ereunon Akademias Athinon

United Kingdom Research And Innovation

Universite De Bordeaux

H. Lundbeck As

Vib Vzw

Institut De Recherches Servier

Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts

Centre National De La Recherche Scientifique Cnrs

Eli Lilly And Company Limited

Janssen Pharmaceutica Nv

The Chancellor

Masters And Scholars Of The University Of Oxford

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).